Control Bionics Limited (ASX:CBL), a neurotechnology company, has disclosed that CEO Jeremy Steele will present at the Bell Potter Healthcare Conference on Wednesday, 18 November at 1:00pm AEDT, where he will provide a business update and discuss growth strategy and near-term catalysts.
Key Points
- Control Bionics will present at the Bell Potter Healthcare Conference, a virtual event running 17–19 November 2026 from 8:30am to 5:30pm AEDT.
- CEO Jeremy Steele will deliver the presentation on Wednesday, 18 November at 1:00pm AEDT.
- The presentation will cover a business update, growth strategy, and near-term catalysts.
- Control Bionics holds regulatory clearances in the US, Australia, and Europe, and is a registered NDIS provider in Australia.
Bell Potter Healthcare Conference Details
The Bell Potter Healthcare Conference is a three-day virtual event scheduled for 17, 18, and 19 November 2026, running from 8:30am to 5:30pm AEDT each day. According to the filing, the conference showcases leading names across ASX biotechnology, medical devices, software, and diagnostics. Participants will have access to business updates, growth strategies, and insights into upcoming catalysts, followed by opportunities for question and answer sessions. Control Bionics described the event as a virtual conference showcasing Australia's best healthcare companies.
CEO Presentation on 18 November
Control Bionics CEO Jeremy Steele is scheduled to present on Wednesday, 18 November at 1:00pm AEDT. The filing states the presentation will include a business update along with a discussion of growth strategy and near-term catalysts. The company disclosed the event as a virtual conference, with shareholders invited to register to attend. No further details regarding the specific content of the business update or the catalysts to be discussed were disclosed in the filing.
Control Bionics Technology Platform
Control Bionics is described in the filing as a neurotechnology company commercialising objective, non-invasive neural-signal technology. Its platform captures physiological signals, including electrical activity generated by muscles, with medical-grade precision and converts them into measurable, decision-ready outcomes. The company disclosed that a single underlying technology platform serves four applications: Performance, Rehabilitation, Research & Data, and Assistive Communication. The filing states the technology does not require surgery or implantation and that the company holds regulatory clearances in the US, Australia, and Europe.



Please wait processing your request...